Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib
and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast
cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients
with metTNBC with locoregional recurrence.